Preterm Premature Rupture of Membranes Clinical Trial
Official title:
A Double-blinded Randomized Controlled Trial With Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM) Between 24 and 32 Weeks Gestation
The purpose of this study is to determine if the short term use of indomethacin will reduce the number of women delivering within 48 hours when given to women with preterm premature rupture of membranes (PPROM) between 24- 32 weeks of gestation. We hypothesize that indomethacin's anti-inflammatory and tocolytic action will reduce the number of women delivering within 48 hours when given to women with PPROM between 24-32 weeks of gestation.
Preterm premature rupture of membranes (PPROM) is defined as rupture of the chorioamniotic
membranes before the onset of labor prior to 37 weeks of gestation. The etiology of PPROM is
not well understood but likely to be multifactorial. Although the underlying mechanism of
PPROM is unknown, some speculate it is the human's inflammatory response to bacterial
infection with the subsequent production of prostaglandins which weaken the fetal membranes.
Therefore, the use of indomethacin, a prostaglandin inhibitor, may decrease prostaglandin
synthesis leading to less uterine irritability and prevention of weakened membranes.
This is a double blind randomized controlled trial comparing indomethacin to placebo in
women with PPROM between the gestational ages of 24-32 weeks. Women between the gestational
age of 24 to 32 weeks with premature rupture of membranes and not in active labor will be
eligible for this clinical trial. After informed consent, patients will be randomized to
either indomethacin or placebo. Maternal and neonatal outcomes will be assessed.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01431248 -
PPROM Erythromycin Versus Azithromycin
|
N/A | |
| Active, not recruiting |
NCT04588220 -
Melatonin, Soluble Urokinase-type Plasminogen Activator Receptor, and Orosomucoid 2 Levels in PPROM
|
||
| Completed |
NCT02314728 -
Cervical Ripening in Premature Rupture of Membranes
|
N/A | |
| Not yet recruiting |
NCT01152528 -
Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery
|
Phase 3 | |
| Completed |
NCT02702297 -
Multimodal Monitoring of Fetal Risk of Inflammation in Preterm Premature Rupture of Membranes
|
||
| Not yet recruiting |
NCT02635451 -
The Relation Between Serum Ascorbic Acid Concentration and Preterm Premature Rupture of Membranes
|
N/A | |
| Completed |
NCT01266928 -
Does Vitamins C and E Supplementation of After Preterm Rupture of Membranes Prolong the Duration of Latency? A Prospective Randomized Controlled Study
|
Phase 3 | |
| Active, not recruiting |
NCT04532021 -
Matrix Metalloproteinase 14, Neopterin, and Orosomucoid 1 Levels in PPROM
|
||
| Recruiting |
NCT02548013 -
Preterm Premature Rupture of Membranes, Outpatient Management vs Inpatient Management
|
N/A | |
| Recruiting |
NCT01584323 -
Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes
|
N/A | |
| Terminated |
NCT00463736 -
Magnesium Sulfate Versus Placebo for Tocolysis in PPROM
|
N/A |